<?xml version="1.0" encoding="UTF-8"?><abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:dn="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/abstract/scopus_id/85127694082</prism:url><dc:identifier>SCOPUS_ID:85127694082</dc:identifier><eid>2-s2.0-85127694082</eid><pubmed-id>35346768</pubmed-id><pii>S0168365922001808</pii><prism:doi>10.1016/j.jconrel.2022.03.046</prism:doi><dc:title>The replacement of helper lipids with charged alternatives in lipid nanoparticles facilitates targeted mRNA delivery to the spleen and lungs</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><citedby-count>8</citedby-count><prism:publicationName>Journal of Controlled Release</prism:publicationName><dc:publisher>Elsevier B.V.</dc:publisher><source-id>23010</source-id><prism:issn>18734995 01683659</prism:issn><prism:volume>345</prism:volume><prism:startingPage>819</prism:startingPage><prism:endingPage>831</prism:endingPage><prism:pageRange>819-831</prism:pageRange><prism:coverDate>2022-05-01</prism:coverDate><openaccess>1</openaccess><openaccessFlag>true</openaccessFlag><dc:creator><author seq="1" auid="57714796300"><ce:initials>S.T.</ce:initials><ce:indexed-name>LoPresti S.T.</ce:indexed-name><ce:surname>LoPresti</ce:surname><ce:given-name>Samuel T.</ce:given-name><preferred-name><ce:initials>S.T.</ce:initials><ce:indexed-name>LoPresti S.T.</ce:indexed-name><ce:surname>LoPresti</ce:surname><ce:given-name>Samuel T.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/57714796300</author-url><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"/></author></dc:creator><dc:description><abstract xmlns="" original="y" xml:lang="eng"><publishercopyright>Â© 2022 The Authors</publishercopyright><ce:para>The broad clinical application of mRNA therapeutics has been hampered by a lack of delivery vehicles that induce protein expression in extrahepatic organs and tissues. Recently, it was shown that mRNA delivery to the spleen or lungs is possible upon the addition of a charged lipid to a standard four-component lipid nanoparticle formulation. This approach, while effective, further complicates an already complex drug formulation and has the potential to slow regulatory approval and adversely impact manufacturing processes. We were thus motivated to maintain a four-component nanoparticle system while achieving shifts in tropism. To that end, we replaced the standard helper lipid in lipidoid nanoparticles, DOPE, with one of eight alternatives. These lipids included the neutral lipids, DOPC, sphingomyelin, and ceramide; the anionic lipids, phosphatidylserine (PS), phosphatidylglycerol, and phosphatidic acid; and the cationic lipids, DOTAP and ethyl phosphatidylcholine. While neutral helper lipids maintained protein expression in the liver, anionic and cationic lipids shifted protein expression to the spleen and lungs, respectively. For example, replacing DOPE with DOTAP increased positive LNP surface charge at pH 7 by 5-fold and altered the ratio of liver to lung protein expression from 36:1 to 1:56. Similarly, replacing DOPE with PS reduced positive charge by half and altered the ratio of liver to spleen protein expression from 8:1 to 1:3. Effects were consistent across ionizable lipidoid chemistries. Regarding mechanism, nanoparticles formulated with neutral and anionic helper lipids best transfected epithelial and immune cells, respectively. Further, the lung-tropic effect of DOTAP was linked to reduced immune cell infiltration of the lungs compared to neutral or anionic lipids. Together, these data show that intravenous non-hepatocellular mRNA delivery is readily achievable while maintaining a four-component formulation with modified helper lipid chemistry.</ce:para></abstract></dc:description><link href="https://api.elsevier.com/content/abstract/scopus_id/85127694082" rel="self"/><link href="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=85127694082&amp;origin=inward" rel="scopus"/><link href="https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&amp;scp=85127694082&amp;origin=inward" rel="scopus-citedby"/></coredata><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"><affilname>Carnegie Mellon University</affilname><affiliation-city>Pittsburgh</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><authors><author seq="1" auid="57714796300"><ce:initials>S.T.</ce:initials><ce:indexed-name>LoPresti S.T.</ce:indexed-name><ce:surname>LoPresti</ce:surname><ce:given-name>Samuel T.</ce:given-name><preferred-name><ce:initials>S.T.</ce:initials><ce:indexed-name>LoPresti S.T.</ce:indexed-name><ce:surname>LoPresti</ce:surname><ce:given-name>Samuel T.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/57714796300</author-url><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"/></author><author seq="2" auid="57215684667"><ce:initials>M.L.</ce:initials><ce:indexed-name>Arral M.L.</ce:indexed-name><ce:surname>Arral</ce:surname><ce:given-name>Mariah L.</ce:given-name><preferred-name><ce:initials>M.L.</ce:initials><ce:indexed-name>Arral M.L.</ce:indexed-name><ce:surname>Arral</ce:surname><ce:given-name>Mariah L.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/57215684667</author-url><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"/></author><author seq="3" auid="57218191561"><ce:initials>N.</ce:initials><ce:indexed-name>Chaudhary N.</ce:indexed-name><ce:surname>Chaudhary</ce:surname><ce:given-name>Namit</ce:given-name><preferred-name><ce:initials>N.</ce:initials><ce:indexed-name>Chaudhary N.</ce:indexed-name><ce:surname>Chaudhary</ce:surname><ce:given-name>Namit</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/57218191561</author-url><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"/></author><author seq="4" auid="35609935600"><ce:initials>K.A.</ce:initials><ce:indexed-name>Whitehead K.A.</ce:indexed-name><ce:surname>Whitehead</ce:surname><ce:given-name>Kathryn A.</ce:given-name><preferred-name><ce:initials>K.A.</ce:initials><ce:indexed-name>Whitehead K.A.</ce:indexed-name><ce:surname>Whitehead</ce:surname><ce:given-name>Kathryn A.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/35609935600</author-url><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"/><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"/></author></authors></abstracts-retrieval-response>